VYNE Therapeutics Inc. (NASDAQ:VYNE) Declares $0.38 Special Dividend

VYNE Therapeutics Inc. (NASDAQ:VYNE) declared a special dividend on Friday, July 10th. Shareholders of record on Wednesday, July 22nd will be given a dividend of 0.38 per share on Thursday, July 23rd. The ex-dividend date is Wednesday, July 22nd.

VYNE Therapeutics Stock Down 5.1%

Shares of NASDAQ VYNE traded down $0.03 during trading on Friday, hitting $0.64. The company had a trading volume of 16,004,494 shares, compared to its average volume of 374,010. The stock has a fifty day simple moving average of $0.66 and a two-hundred day simple moving average of $0.62. VYNE Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $1.59. The firm has a market capitalization of $21.26 million, a price-to-earnings ratio of -1.68 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.20 million. On average, analysts anticipate that VYNE Therapeutics will post -1.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VYNE. Rangeley Capital LLC lifted its position in VYNE Therapeutics by 18.1% in the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after buying an additional 18,064 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of VYNE Therapeutics in the 4th quarter valued at approximately $46,000. Geode Capital Management LLC raised its stake in shares of VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after acquiring an additional 88,030 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of VYNE Therapeutics in the 2nd quarter worth approximately $176,000. Finally, Jane Street Group LLC purchased a new position in shares of VYNE Therapeutics during the 2nd quarter worth approximately $206,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.